ArticleNutrition & metabolism2026
Visceral fat metabolism score and cardiovascular-kidney-metabolic syndrome stages in all-cause and cause-specific mortality: insights from UK Biobank.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe roles of Cardiovascular-Kidney-Metabolic Syndrome (CKM) staging and the emerging obesity marker Visceral Fat Metabolism Score (METS-VF) in cause-specific mortality, as well as their potential interaction, remain to be further investigated.
methods396,383 UK Biobank participants were analyzed. Primary outcomes included all-cause and cause-specific deaths, including cardiovascular, respiratory, digestive, neurodegenerative diseases, cancer, and other causes. Independent and joint effects of METS-VF and CKM were evaluated using a COX proportional hazards regression model, with multiple sensitivity analyses conducted to verify robustness. Dose–response relationships were visualized using restricted cubic spline (RCS) curves. Receiver operating characteristic (ROC) analyses were conducted to evaluate the discriminative performance of METS-VF for predicting mortality compared with other obesity-related indices. Multiple sensitivity analyses were further performed to assess the robustness of the findings.
resultsOver an average follow-up of 12.51 years, 34,471 deaths were recorded. After multivariate adjustment, both METS-VF and CKM stage were associated with all-cause mortality. The hazard ratio for the highest METS-VF quartile was 1.70 (95% CI: 1.61–1.80), and for the highest CKM stage was 2.23 (95% CI: 2.12–2.35). Each 0.1 increase in METS-VF raised the risk of death by 8.2% (CVD), 3.5% (respiratory), 8.8% (digestive), 2.7% (cancer), and 6.9% (other causes). RCS analysis showed a non-linear relationship between METS-VF and mortality. ROC analyses further demonstrated that METS-VF exhibited significantly higher predictive performance for both all-cause and cause-specific mortality compared to other obesity-related indices. Joint analysis revealed that participants with stage IV CKM and high METS-VF had the highest risks of all-cause and cause-specific mortality, with synergistic effects noted for CVD, and digestive mortality.
conclusionHigh METS-VF and late-stage CKM were associated with increased risks of mortality from multiple causes. For individuals with late-stage CKM, enhanced assessment of METS-VF is recommended to facilitate timely interventions and reduce mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.